Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in CHF (TTM)47.20bn
  • Net income in CHF6.36bn
  • Incorporated1996
  • Employees103.00k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lonza Group AG6.22bn1.22bn42.60bn17.49k35.004.0123.496.8416.3416.3483.69142.660.36812.285.95355,722.007.205.308.636.4839.1839.9019.5715.201.2721.610.173128.4115.056.4780.2712.8432.934.94
Bayer AG49.03bn2.95bn51.90bn101.74k17.601.315.601.063.093.0951.3941.600.40261.673.46498,071.402.44-1.113.30-1.4559.5458.986.05-3.040.75874.950.5135--15.107.70315.005.024.50-2.72
GSK plc32.51bn4.85bn63.73bn69.40k12.634.828.131.961.103.647.522.890.39231.513.84419,092.206.456.399.8210.4270.4269.5516.4415.900.6949.710.648993.3718.74-0.577851.7310.270.5035-5.53
Sanofi SA44.87bn8.12bn121.86bn91.57k14.95--11.932.726.656.6536.84--------504,504.60--5.80--7.0269.9368.4918.2417.00--102.64--59.8415.864.6234.5217.282.393.28
Novartis AG47.20bn6.36bn202.45bn103.00k30.223.9617.724.292.942.9421.7822.470.43912.036.02464,083.905.929.097.9511.7771.0970.9813.4823.680.793112.260.358659.94-2.153.60-71.05-1.493.093.79
AstraZeneca plc39.70bn4.26bn203.79bn83.50k48.146.2921.685.132.442.4422.7718.710.44521.354.62425,359.104.782.636.313.6280.6378.9910.746.350.69596.820.468187.0718.5314.572,835.716.639.681.13
Roche Holding AG63.28bn12.42bn237.82bn103.61k18.938.3013.693.7615.3615.3678.3235.030.70132.275.65610,743.8015.0016.2125.3125.3370.7571.0721.3822.620.925619.250.441959.330.76433.49-10.837.262.632.74
Novo Nordisk A/S24.55bn7.97bn254.81bn57.09k42.3232.0328.8410.3826.8826.8882.7135.520.84221.294.343,461,659.0027.3429.8355.6758.5884.2283.7632.4732.860.669416.840.242145.8825.689.6416.277.8111.279.57
Data as of May 26 2023. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF

Institutional shareholders

16.72%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 May 202357.37m2.52%
UBS Asset Management Switzerland AGas of 31 Dec 202255.73m2.45%
Norges Bank Investment Managementas of 31 Dec 202254.67m2.40%
Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 202250.01m2.20%
Wellington Management Co. LLPas of 04 May 202344.72m1.96%
BlackRock Fund Advisorsas of 04 May 202338.55m1.69%
Z�rcher Kantonalbank (Investment Management)as of 31 Jan 202323.08m1.01%
Dodge & Coxas of 31 Mar 202319.44m0.85%
Artisan Partners LPas of 31 Mar 202318.94m0.83%
BlackRock Advisors (UK) Ltd.as of 04 May 202318.19m0.80%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.